ELITE PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1662 USD | -1.07% |
|
-1.31% | +18.71% |
| May. 20 | Elite Pharmaceuticals Receives Fda Approval for Generic Methotrexate | CI |
| Feb. 15 | Transcript : Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Generic Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 179M | - | - | - | - | - | |
| 43.26B | ||||||
| 21.6B | ||||||
| 15.93B | ||||||
| 15.1B | ||||||
| 12.95B |
